In a recent interview, Sherry Shen, M.D., discussed the potential impact of FES PET recently being recommended by the National Comprehensive Cancer Network (NCCN) Guidelines for the staging of recurrent or metastatic estrogen receptor-positive (ER+) lobular breast cancer.

Read the full article on diagnosticimaging.com